{"protocolSection":{"identificationModule":{"nctId":"NCT00854308","orgStudyIdInfo":{"id":"OAM4558g"},"organization":{"fullName":"Genentech, Inc.","class":"INDUSTRY"},"briefTitle":"A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)","officialTitle":"A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Activity of MetMAb, a Monovalent Antagonist Antibody to the Receptor Met, Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)"},"statusModule":{"statusVerifiedDate":"2012-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-04"},"primaryCompletionDateStruct":{"date":"2010-11","type":"ACTUAL"},"completionDateStruct":{"date":"2012-01","type":"ACTUAL"},"studyFirstSubmitDate":"2009-02-27","studyFirstSubmitQcDate":"2009-02-27","studyFirstPostDateStruct":{"date":"2009-03-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-09-09","resultsFirstSubmitQcDate":"2011-09-09","resultsFirstPostDateStruct":{"date":"2011-10-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-03-02","lastUpdatePostDateStruct":{"date":"2017-03-31","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Genentech, Inc.","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell Lung Cancer (NSCLC). Up to 180 patients will be randomized in a 1:1 ratio to one of the two treatment arms."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"],"keywords":["Tarceva","Lung Cancer","NSCLC"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":137,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MetMAb + Erlotinib","type":"EXPERIMENTAL","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.","interventionNames":["Drug: Erlotinib HCl","Drug: MetMAb"]},{"label":"Placebo + Erlotinib","type":"PLACEBO_COMPARATOR","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.","interventionNames":["Drug: Erlotinib HCl","Drug: placebo (0.9 % saline)"]}],"interventions":[{"type":"DRUG","name":"Erlotinib HCl","description":"Erlotinib 150 mg oral dose once daily.","armGroupLabels":["MetMAb + Erlotinib","Placebo + Erlotinib"],"otherNames":["Tarceva"]},{"type":"DRUG","name":"MetMAb","description":"MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.","armGroupLabels":["MetMAb + Erlotinib"]},{"type":"DRUG","name":"placebo (0.9 % saline)","description":"Placebo Intravenous infusion every 3 weeks.","armGroupLabels":["Placebo + Erlotinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival","description":"Progression-free survival was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).","timeFrame":"Time from randomization to the first occurrence of progression/relapse or death on study. (Up to 20 months)"},{"measure":"Progression-free Survival in Patients With Met Diagnostic-Positive Tumors","description":"Progression-free survival (PFS) in participants with Met Diagnostic-Positive tumors as determined by immunohistochemistry.\n\nPFS was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).","timeFrame":"Time from randomization to the first occurrence of progression/relapse or death on study. (Up to 20 months)"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With Objective Response","description":"Objective response (partial and complete response as determined using RECIST 1.0).\n\nPartial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter.\n\nComplete response was defined as disappearance of all target lesions.","timeFrame":"Start of treatment until disease progression/recurrence or death on study. (Up to 20 months)"},{"measure":"Percentage of Participants With Objective Response in Patients With Met Diagnostic-Positive Tumors","description":"Objective response (OR); partial and complete response as determined using RECIST 1.0 in patients with Met Diagnostic-Positive Tumors as determined by immunohistochemistry.\n\nPartial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter.\n\nComplete response was defined as disappearance of all target lesions.","timeFrame":"Start of treatment until disease progression/recurrence or death on study. (Up to 20 months)"},{"measure":"Duration of Overall Response","timeFrame":"Date of initial response until date of progression or death on study. (Up to 20 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients must meet the following criteria for study entry:\n\n* Histologically confirmed NSCLC\n* Availability of a tumor specimen\n* Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease\n* Measurable disease in accordance with Response Evaluation Criteria in Solid Tumors (RECIST)\n* At least one measurable lesion on a pre-treatment 18-fluorodeoxyglcose-positron emission tomography (FDG-PET) scan that is also a target lesion on computed tomography (CT) according to RECIST\n\nExclusion Criteria:\n\n* More than two prior treatments for Stage IIIB/IV\n* More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known epidermal growth factor receptor (EGFR)-related toxicity resulting in dose modifications\n* Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization\n* Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) central nervous system (CNS) metastasis\n* History of serious systemic disease within the past 6 months prior to randomization\n* Uncontrolled diabetes\n* Major surgical procedure or significant traumatic injury within 28 days prior to randomization\n* Anticipation of need for a major surgical procedure during the course of the study\n* Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization\n* Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Premal Patel, M.D., Ph.D.","affiliation":"Genentech, Inc.","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Twenty-seven patients in the placebo + erlotinib arm with disease progression in the blinded treatment stage elected to receive MetMAb + erlotinib in the optional open-label phase of the study.","groups":[{"id":"FG000","title":"MetMAb + Erlotinib","description":"MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"FG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"68"}]},{"type":"Received Study Drug","achievements":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"67"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Completed participants in both arms were still receiving study drug when analyses were performed.","numSubjects":"7"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"67"}]}],"dropWithdraws":[{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"50"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Sponsor's decision to terminate study","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"BG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"137"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.6","spread":"9.4"},{"groupId":"BG001","value":"62.7","spread":"10.6"},{"groupId":"BG002","value":"63.1","spread":"10.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"29"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"55"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"82"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"Progression-free survival was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).","populationDescription":"All randomized intent-to-treat patients.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from randomization to the first occurrence of progression/relapse or death on study. (Up to 20 months)","groups":[{"id":"OG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"OG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.38","upperLimit":"2.86"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.45","upperLimit":"2.76"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no difference in PFS between MetMab + Erlotinib and Placebo + Erlotinib. The alternate hypothesis is that MetMab + Erlotinib would have prolonged PFS compared with Placebo + Erlotinib.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6873","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.086","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.727","ciUpperLimit":"1.622","estimateComment":"The hazard ratio was estimated using Cox Regression and was stratified for smoking status, Eastern Cooperative Oncology Group (ECOG) performance status and histology. The hazard ratio is relative to Placebo + Erlotinib."}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response","description":"Objective response (partial and complete response as determined using RECIST 1.0).\n\nPartial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter.\n\nComplete response was defined as disappearance of all target lesions.","populationDescription":"All randomized intent-to-treat patients.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Start of treatment until disease progression/recurrence or death on study. (Up to 20 months)","groups":[{"id":"OG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"OG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"68"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"2.0","upperLimit":"13.9"},{"groupId":"OG001","value":"4.4","lowerLimit":"1.2","upperLimit":"11.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no difference in Objective Response between MetMab + Erlotinib and Placebo + Erlotinib. The alternate hypothesis is that MetMab + Erlotinib would have better Objective Response compared with Placebo + Erlotinib.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.7101","pValueComment":"P-value was stratified for smoking status, ECOG performance status and histology.","statisticalMethod":"Cochran-Mantel-Haenszel","ciPctValue":"95"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response in Patients With Met Diagnostic-Positive Tumors","description":"Objective response (OR); partial and complete response as determined using RECIST 1.0 in patients with Met Diagnostic-Positive Tumors as determined by immunohistochemistry.\n\nPartial response was defined as at least a 30% decrease in the sum of the longest diameter of target lesions taking as reference the baseline sum longest diameter.\n\nComplete response was defined as disappearance of all target lesions.","populationDescription":"All randomized intent-to-treat patients with Met Diagnostic-positive tumors.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Start of treatment until disease progression/recurrence or death on study. (Up to 20 months)","groups":[{"id":"OG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"OG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"2.4","upperLimit":"21.5"},{"groupId":"OG001","value":"3.2","lowerLimit":"0.2","upperLimit":"16.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no difference in Objective Response between MetMab + Erlotinib and Placebo + Erlotinib. The alternate hypothesis is that MetMab + Erlotinib would have better Objective Response compared with Placebo + Erlotinib","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3671","pValueComment":"P-value was stratified for smoking status, ECOG performance status and histology.","statisticalMethod":"Cochran-Mantel-Haenszel","ciPctValue":"95"}]},{"type":"PRIMARY","title":"Progression-free Survival in Patients With Met Diagnostic-Positive Tumors","description":"Progression-free survival (PFS) in participants with Met Diagnostic-Positive tumors as determined by immunohistochemistry.\n\nPFS was defined as the time from randomization to the first occurrence of progression or relapse (as per Response Evaluation Criteria in Solid Tumors (RECIST 1.0) and assessed by the site radiologist or investigator) or death on study from any cause (within 30 days of last treatment).","populationDescription":"All randomized intent-to-treat patients with Met Diagnostic-Positive tumors.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Time from randomization to the first occurrence of progression/relapse or death on study. (Up to 20 months)","groups":[{"id":"OG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"OG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"31"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","lowerLimit":"1.38","upperLimit":"6.21"},{"groupId":"OG001","value":"1.5","lowerLimit":"1.35","upperLimit":"2.63"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The null hypothesis is that there is no difference in PFS between MetMab + Erlotinib and Placebo + Erlotinib. The alternate hypothesis is that MetMab + Erlotinib would have prolonged PFS compared with Placebo + Erlotinib.","nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0418","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.529","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.284","ciUpperLimit":"0.986","estimateComment":"The hazard ratio was estimated using Cox Regression and was stratified for smoking status, ECOG performance status and histology. The hazard ratio is relative to Placebo + Erlotinib."}]},{"type":"SECONDARY","title":"Duration of Overall Response","populationDescription":"All randomized intent-to-treat patients. Analyses of duration of response were not performed because of the small number of patients with objective responses.","reportingStatus":"POSTED","timeFrame":"Date of initial response until date of progression or death on study. (Up to 20 months)","groups":[{"id":"OG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity."},{"id":"OG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 20 months","eventGroups":[{"id":"EG000","title":"MetMAb + Erlotinib","description":"MetMab 15 mg/kg intravenous (IV) infusion every 3 weeks + Erlotinib 150 mg orally once daily until progression of disease or unacceptable toxicity.","seriousNumAffected":29,"seriousNumAtRisk":69,"otherNumAffected":68,"otherNumAtRisk":69},{"id":"EG001","title":"Placebo + Erlotinib","description":"Placebo IV infusion every 3 weeks + Erlotinib 150 mg orally daily until progression of disease or unacceptable toxicity.","seriousNumAffected":22,"seriousNumAtRisk":67,"otherNumAffected":67,"otherNumAtRisk":67}],"seriousEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"ATRIAL FIBRILLATION","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"CARDIAC ARREST","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"TACHYCARDIA","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"ADRENAL INSUFFICIENCY","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"DEATH","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"HERNIA OBSTRUCTIVE","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"HYPERSENSITIVITY","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"LUNG INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"CELLULITIS","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"STAPHYLOCOCCAL INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"DEHYDRATION","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"HYPOGLYCAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"HYPOVOLAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"CEREBRAL INFARCTION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"CEREBROVASCULAR ACCIDENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"SPINAL CORD COMPRESSION","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"SYNCOPE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"DELIRIUM","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"RENAL FAILURE","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"CHRONIC OBSTRUCTIVE PULMONARY DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"INTERSTITIAL LUNG DISEASE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"RESPIRATORY DISTRESS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"HYPOXIA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"OBSTRUCTIVE AIRWAYS DISORDER","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"PNEUMONIA ASPIRATION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"PULMONARY ARTERY THROMBOSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"RESPIRATORY FAILURE","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"DEEP VEIN THROMBOSIS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"EMBOLISM VENOUS","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"ORTHOSTATIC HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"SUPERIOR VENA CAVAL OCCLUSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":0,"numAtRisk":67}]}],"otherEvents":[{"term":"ANAEMIA","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":69},{"groupId":"EG001","numAffected":10,"numAtRisk":67}]},{"term":"DIARRHOEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":69},{"groupId":"EG001","numAffected":35,"numAtRisk":67}]},{"term":"NAUSEA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":69},{"groupId":"EG001","numAffected":21,"numAtRisk":67}]},{"term":"VOMITING","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":13,"numAtRisk":67}]},{"term":"DYSPEPSIA","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":69},{"groupId":"EG001","numAffected":6,"numAtRisk":67}]},{"term":"CONSTIPATION","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":5,"numAtRisk":67}]},{"term":"ABDOMINAL PAIN","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"STOMATITIS","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]},{"term":"FATIGUE","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":69},{"groupId":"EG001","numAffected":24,"numAtRisk":67}]},{"term":"OEDEMA PERIPHERAL","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":69},{"groupId":"EG001","numAffected":5,"numAtRisk":67}]},{"term":"PYREXIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":69},{"groupId":"EG001","numAffected":6,"numAtRisk":67}]},{"term":"ASTHENIA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":69},{"groupId":"EG001","numAffected":6,"numAtRisk":67}]},{"term":"PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":8,"numAtRisk":67}]},{"term":"CHEST PAIN","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":7,"numAtRisk":67}]},{"term":"OEDEMA","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"URINARY TRACT INFECTION","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":6,"numAtRisk":67}]},{"term":"PNEUMONIA","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]},{"term":"DECREASED APPETITE","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":69},{"groupId":"EG001","numAffected":16,"numAtRisk":67}]},{"term":"HYPOKALAEMIA","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":5,"numAtRisk":67}]},{"term":"BACK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":69},{"groupId":"EG001","numAffected":7,"numAtRisk":67}]},{"term":"ARTHRALGIA","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]},{"term":"MUSCLE SPASMS","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]},{"term":"MUSCULOSKELETAL CHEST PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]},{"term":"MUSCULOSKELETAL PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":4,"numAtRisk":67}]},{"term":"PAIN IN EXTREMITY","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":4,"numAtRisk":67}]},{"term":"NECK PAIN","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":69},{"groupId":"EG001","numAffected":4,"numAtRisk":67}]},{"term":"DIZZINESS","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":69},{"groupId":"EG001","numAffected":6,"numAtRisk":67}]},{"term":"DYSGEUSIA","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":69},{"groupId":"EG001","numAffected":4,"numAtRisk":67}]},{"term":"HEADACHE","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":69},{"groupId":"EG001","numAffected":4,"numAtRisk":67}]},{"term":"ANXIETY","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":69},{"groupId":"EG001","numAffected":7,"numAtRisk":67}]},{"term":"INSOMNIA","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":69},{"groupId":"EG001","numAffected":5,"numAtRisk":67}]},{"term":"DYSPNOEA","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":69},{"groupId":"EG001","numAffected":16,"numAtRisk":67}]},{"term":"COUGH","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":69},{"groupId":"EG001","numAffected":13,"numAtRisk":67}]},{"term":"HAEMOPTYSIS","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":69},{"groupId":"EG001","numAffected":5,"numAtRisk":67}]},{"term":"PLEURAL EFFUSION","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":2,"numAtRisk":67}]},{"term":"PULMONARY EMBOLISM","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":1,"numAtRisk":67}]},{"term":"RASH","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":69},{"groupId":"EG001","numAffected":41,"numAtRisk":67}]},{"term":"DERMATITIS ACNEIFORM","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":69},{"groupId":"EG001","numAffected":10,"numAtRisk":67}]},{"term":"DRY SKIN","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":69},{"groupId":"EG001","numAffected":10,"numAtRisk":67}]},{"term":"PRURITUS","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":69},{"groupId":"EG001","numAffected":8,"numAtRisk":67}]},{"term":"HYPOTENSION","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":69},{"groupId":"EG001","numAffected":3,"numAtRisk":67}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffman-LaRoche","phone":"800-821-8590"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Australia","Canada","France","Poland","Russia","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D008175","term":"Lung Neoplasms"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069347","term":"Erlotinib Hydrochloride"},{"id":"C584058","term":"onartuzumab"},{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}